Clinical Valve Thrombosis and Subclinical Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Is There a Need for a Patient-Tailored Antithrombotic Therapy?

Clinical Valve Thrombosis and Subclinical Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Is There a Need for a Patient-Tailored Antithrombotic Therapy?

Transcatheter aortic valve replacement (TAVR) has become an established therapeutic option for patients with symptomatic, severe aortic valve stenosis at increased surgical risk. Antithrombotic therapy after TAVR aims to prevent transcatheter heart valve (THV) thrombosis, in which two different enti...

Full description

Bibliographic Details
Main Authors: Liesbeth Rosseel, Ole De Backer, Lars Søndergaard
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
aortic valve replacement
transcatheter
clinical valve thrombosis
subclinical leaflet thrombosis
antithrombotic therapy
Online Access:https://www.frontiersin.org/article/10.3389/fcvm.2019.00044/full

Internet

https://www.frontiersin.org/article/10.3389/fcvm.2019.00044/full

Similar Items